Abstract 2401P
Background
Transurethral resection of bladder tumor (TURBT) is the primary treatment for early-stage bladder cancer, and early detection of tumor recurrence is vital for improving patient outcome. Non-invasive and reliable methods for monitoring molecular changes in urine represent a promising avenue to facilitate timely intervention and effective disease management.
Methods
In this ongoing prospective study, 95 patients with early-stage bladder cancer were recruited, whose urine samples were collected prior to TURBT. Afterward, patients were advised to provide urine samples during follow-up visits. PredicineCARE, a targeted next-generation sequencing (NGS) liquid biopsy assay, was employed to identify somatic alterations in urinary tumor DNA (utDNA). Based on these alterations, the tumor fraction was assessed to identify molecular recurrence in the patients.
Results
Out of the 95 patients, 48 were diagnosed with non-muscle invasive bladder cancer (NMIBC) and 47 with muscle invasive bladder cancer (MIBC). The genes that showed the most frequent variations in NMIBC patients were TP53 (54%), TERT (46%), FGFR3 (31%), ERCC2 (31%), ARID1A (31%), and CDKN2A (31%). Meanwhile, in MIBC, the most frequently varied genes were TP53 (74%), TERT (47%), PIK3CA (32%), and KDM6A (32%). 38.5% of NMIBC patients and 26.3% of MIBC patients harbored FGFR2/3 variations, suggesting that they could potentially benefit from FGFR inhibitors. Among the 29 patients with follow-up data, longitudinal urine samples of 12 patients (2 NMIBC, 10 MIBC) were tested. Nine patients (2 NMIBC, 7 MIBC) showed a significant decrease in tumor fraction, one (MIBC) remained stable, and two patients (MIBC) exhibited increasing tumor fraction, indicating molecular recurrence of the disease.
Conclusions
The results of this study confirm the validity of utilizing a utDNA assay to detect molecular recurrence in early-stage bladder cancer patients who have undergone TURBT treatment, which can be instrumental in facilitating early detection of tumor recurrence and guiding treatment decisions. These findings underscore the enormous potential of urine-based NGS assays for urothelial cancer detection and disease surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2380P - Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)
Presenter: Nicolas Sayegh
Session: Poster session 24
2381P - Perceived unmet needs and challenges faced by patients with advanced bladder cancer (aBC) and their caregivers: Results of a social media listening (SML) study conducted in 5 European countries
Presenter: Stephane Schuck
Session: Poster session 24
2382P - EBANO study: Clinical characteristics, treatment patterns and survival results in patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in northern Spain
Presenter: Ricardo Fernandez-Rodriguez
Session: Poster session 24
2383P - Stereotactic body radiotherapy (SBRT) of patients with oligometastatic urothelial cancer (UC): A single institution experience
Presenter: Faith Jawdat
Session: Poster session 24
2384P - Platinum rechallenge in the era of immune checkpoint inhibitor in locally advanced/metastatic urothelial carcinoma: Multicenter retrospective study
Presenter: Eojin Kim
Session: Poster session 24
2385P - Long-term survival upon anti-PD-(L)1 monotherapy in metastatic urothelial cancer (mUC): A multicenter retrospective study
Presenter: Chantal Stockem
Session: Poster session 24
2386P - Factors associated with not receiving systemic treatment (tx) in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 24
2387P - Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
Presenter: Kenneth Carson
Session: Poster session 24
2390P - Correlation between overall survival and bladder-intact event-free survival in cystectomy-ineligible/refusal muscle-invasive bladder cancer patients in Sweden
Presenter: Kelvin Kwok
Session: Poster session 24